Navigation Links
BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
Date:7/28/2008

s that could affect the forward-looking statements contained herein include that our belief that many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by intramuscular injection may not be correct, that HHS and the Food & Drug Administration (FDA) may not agree with our analysis, that HHS may further condition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the peramivir program may not be successful, that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future preclinical and clinical development may not have positive results, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not be able to retain its current pharmaceutical and biotechnology partners for further development of its product candidates or it may not reach favorable agreements with potential pharmaceutical and biotechnology partners for further development of its product candidates, that our projected burn rate may not be consistent with our expectations, that BioCryst may not have sufficient cash to continue funding the development, manuf
'/>"/>
SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza
2. BioCryst Updates Peramivir Clinical Development Plan
3. BioCryst Provides Forodesine HCl Update
4. BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymphoma (CTCL)
5. Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
6. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
7. Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials
8. GeoVax Reports Progress on Its AIDS Vaccine Technology
9. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
10. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
11. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... VIEJO, Calif. , Dec. 22, 2014 ... into expanded corporate offices in Aliso Viejo ... announced that due to the tremendous growth and worldwide ... needed. Sales of patented SnoreRx, the anti snore cure ... offices. He said, "We are now in 23 ...
(Date:12/22/2014)... 22, 2014 Research and Markets ... the "Investment Analysis of the US Medical ... http://photos.prnewswire.com/prnh/20130307/600769 ... medical device sector identifies the key trends and ... investments, and mergers and acquisitions. The ...
(Date:12/22/2014)... , Dec. 22, 2014 Swedish Orphan ... today announced that the Committee for Medicinal Products for ... has adopted a positive opinion for the use of ... men with Peyronie,s disease with a palpable plaque and ... start of therapy. The use of Xiapex ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
... July 27 Timothy Mastro,MD, FACP, DTM&H, who ... Senior Director of Research, will share information on ... at the,International AIDS Conference in Mexico City., ... Trials," will examine ongoing and upcoming clinical trials ...
... advance the company,s clinical development programs and ... CombiPlex(TM) technology ... privately held pharmaceutical company developing novel,products based on proven ... excess of $22.5 million in a Series C private,equity ...
Cached Medicine Technology:HIV Prevention Expert Dr. Timothy Mastro Speaks on Future of Pre-Exposure Prophylaxis at International AIDS Conference 2Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million 2Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million 3
(Date:12/25/2014)... (PRWEB) December 26, 2014 The ... CAGR of 7.2% to reach $5,756.0 million by ... the microscopy market. The electron microscopes product segment ... the forecast period. , Rising focus on nanotechnology, ... growth of the microscopy market. , Get Full ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 ... Market Analysis to 2023” focuses on the current ... opportunities in the colorectal cancer market. Stivarga is ... of colon or rectal cancer. Boehringer Ingelheim is ... for the treatment of refractory CRC in the ...
(Date:12/25/2014)... 2014 “Every three months the trends for ... sweetheart evening dress will be one of the hottest styles ... Yunx.co.uk says. Today, the company releases 26 A-line sweetheart evening ... 80% off. , “We are trying our best to ... our latest designs. Along with affordable prices, we provide discounted ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 The short film ... was created in honor of a true 9/11 hero, Welles ... film festivals including the 24 hours of Nuremberg International Short ... Bangladesh. , Actress, screenwriter and director Luciana Lagana ... this film together with her husband, Gregory Graham ...
(Date:12/25/2014)... Woodland Hills, California (PRWEB) December 25, 2014 ... in her home in Woodland Hills, California after an ... Harris passed away on Christmas Eve evening in her ... battle with aggressive metastatic breast cancer. ... International for over forty years, she pioneered and championed ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... in Ongoing Research to Replicate Insulin-Producing Function of Healthy ... SANTA BARBARA, Calif., March 31 A key step ... patients with diabetes has been achieved, according to new ... Technology & Therapeutics .Researchers at the University of ...
... refractory patients recruited in trial;, ... complete efficacy data to be available in ... Life Sciences Inc. (TSX: BNC), a research-based, technology-driven ... completed recruitment in its initial Phase III registration ...
... in The Journal of Nursing Administration shows ... continuous vigilance monitoring is used on medical-surgical unit beds. ... President and CEO of Hoana Medical, Inc. "Using ... potential patient deterioration so they can respond appropriately. ...
... magazine for medical device makers appoints Full Spectrum Software’s Andrew Dallas ... premier magazine for the medical device industry has appointed Andrew Dallas ... president and CTO of Full Spectrum Software company background ... ...
... Urgent Care Center. Hoboken residents now have much needed option for treatment ... ... -- Hoboken families now have a convenient place to go for most ... Hoboken,s first Urgent Care center and a medical facility like no other ...
... ... Alpharetta, Ga. (PRWEB) March 31, 2009 -- Among 1,239 ... had not worked at a government healthcare facility at least once. ... in trying government locum tenens jobs. This is good news ...
Cached Medicine News:Health News:Researchers Successfully Create Computer-Simulated Model for Evaluating Artificial Pancreas 2Health News:Researchers Successfully Create Computer-Simulated Model for Evaluating Artificial Pancreas 3Health News:Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM) 2Health News:Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM) 3Health News:Continuous Vigilance Monitoring Technology Benefits Nurses & Patients 2Health News:Andrew Dallas, President of Full Spectrum Software Appointed to Medical Device and Diagnostic Industry Magazine Editorial Advisory Board 2Health News:PromptMD Announces the Opening of their First Urgent Care Center at 309 First Street in Hoboken 2Health News:Physician Survey Highlights Advantages of Government Locum Tenens Jobs 2Health News:Physician Survey Highlights Advantages of Government Locum Tenens Jobs 3
... is a leading provider of immunofluorescence assays, ... menu that includes kits for autoimmune diseases, ... miscellaneous conjugates and components. Our Impact IFA ... of substrates and kit sizes to choose ...
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
... ELISA products make us a leader in ... faster integration into the busy laboratory, our ... and run-to-run consistency. Our Infectious Disease ELISA ... wide range of serological assays including ToRCH, ...
... Diagnostics is a leading provider of immunofluorescence ... test menu that includes kits for autoimmune ... as miscellaneous conjugates and components. Our Impact ... assortment of substrates and kit sizes to ...
Medicine Products: